Skip to content
Home » Pharmaceutical » Merck » Page 5

Merck

I get an email about Gardasil

hpv posterI get lots of email about my articles that are published here. Sometimes, it’s about grammar or spelling (and the grammar KGB can be uncivil at times). Sometimes, it’s compliments or questions about what I’ve written. Rarely, they’re rude and usually include quite immature comments about the location of my head. However, I recently received an email that is more or less polite, but is filled with so many errors and logical fallacies, that I thought it should be critiqued publicly.

Here are my point-by-point comments about the email:

I stumbled across your blog and could not believe what I was reading about the safety of Gardasil.  As a mother of a Gardasil injured daughter, your profuse endorsement made me skeptical.  I want to begin by saying I am not anti-vaccine;  I am anti-Gardasil. Read More »I get an email about Gardasil

HPV–early vaccination maximizes effectiveness

 

HPV protesters in Texas.

Human papillomavirus (HPV) is a virus from the papillomavirus family that is capable of infecting humans. Like all papillomaviruses, HPVs establish productive infections only in keratinocytes of the skin or mucous membranes, making it easily transmitted sexually or through other intimate contact. While the majority of the known types of HPV cause no symptoms in most people, some types can cause warts (verrucae). HPV types 16 and 18 cause approximately 70% of cervical cancers, and cause most HPV-induced anal, vulvar, vaginal, and penile cancers. The HPV quadrivalent vaccine, also known as Gardasil (or Silgard in Europe), is marketed by Merck. The vaccine prevents the transmission of certain types of HPV, specifically types 6, 11, 16 and 18

Although the safety of HPV vaccine has been thoroughly vetted for safety in studies with large cohorts, the long time period (up to decades) from infection to a diagnosis of an HPV-related cancer has left questions about how to maximize effectiveness of the vaccine which required further research. Read More »HPV–early vaccination maximizes effectiveness

Why do Americans hate Gardasil?

In next week’s issue of Forbes, Matthew Herper, the magazine’s medical editor, penned the article, The Gardasil Problem: How The U.S. Lost Faith In A Promising Vaccine, an insightful analysis of why Gardasil, the vaccine for human papillomavirus (HPV), has not become as important to vaccination strategies as measles or whooping cough.  All vaccines keep you alive, even if the disease does not appear to be scary.  There’s a belief, especially amongst the anti-vaccination crowd, that measles is just a few spots, and there are few risks to being infected.  The risk of severe complications is small, but significant.

On the other hand, the HPV vaccine does one thing and does it well–it prevents an HPV infection.  Human papillomavirus, a sexually transmitted disease, causes 70% of cervical cancers, 80% of anal cancers, 60% of vaginal cancers, and 40% of vulvar cancers.  It also prevents the majority of HPV caused oral cancers.  In other words, these diseases are in a different league of danger.  And they can be prevented.Read More »Why do Americans hate Gardasil?

CDC makes recommendations on the use of HPV vaccine in males

The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of males aged 11 or 12 years with HPV4 administered as a 3-dose series (recommendation category: A, evidence type: 2§). The vaccination series can be started beginning at age 9 years. Vaccination with HPV4 is recommended for males aged 13 through 21 years who have not been vaccinated previously or who have not completed the 3-dose series. Males aged 22 through 26 years may be vaccinated.Read More »CDC makes recommendations on the use of HPV vaccine in males